CK LIFE SCIENCES INT'L., (HOLDINGS) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.345 HKD | +1.47% |
|
+2.99% | -44.35% |
| 04-05 | CK Life Sciences to Present Pre-Clinical Data for Two Cancer Vaccines; Shares Up 11% | MT |
| 03-19 | CK Life Sciences Int'l., Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 5.28B 674M 53.95B | Sales 2023 | 5.32B 680M 54.44B | Capitalization | 5.96B 761M 60.94B |
|---|---|---|---|---|---|
| Net income 2022 | 132M 16.86M 1.35B | Net income 2023 | 17M 2.17M 174M | EV / Sales 2022 | 2.43 x |
| Net Debt 2022 | 5.24B 670M 53.61B | Net Debt 2023 | 5.25B 671M 53.74B | EV / Sales 2023 | 2.11 x |
| P/E ratio 2022 |
57.5
x | P/E ratio 2023 |
346
x | Employees | 1,932 |
| Yield 2022 |
1.01% | Yield 2023 |
-
| Free-Float | 25.02% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.47% | ||
| 1 week | +2.99% | ||
| Current month | +2.99% | ||
| 3 months | -40.52% | ||
| 6 months | -50.00% | ||
| Current year | -44.35% |
1 week
0.33
0.37
1 month
0.300.42
Current year
0.300.62
1 year
0.300.82
3 years
0.301.28
5 years
0.301.34
10 years
0.301.34
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Choi Yu
CEO | Chief Executive Officer | 69 | 31/05/02 |
Yiu Leung Mo
DFI | Director of Finance/CFO | 64 | 30/09/05 |
Hing Lam Kam
PSD | President | 77 | 31/05/02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eva Lee Kwok
BRD | Director/Board Member | 82 | 31/05/02 |
Tzar Kuoi Li
CHM | Chairman | 59 | 31/03/02 |
Hing Lam Kam
PSD | President | 77 | 31/05/02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.97% | 4 M€ | -27.92% | ||
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.345 | +1.47% | 6,108,600 |
| 25/04/24 | 0.34 | -1.45% | 8,846,142 |
| 24/04/24 | 0.345 | +2.99% | 2,165,080 |
| 23/04/24 | 0.335 | -1.47% | 1,856,000 |
| 22/04/24 | 0.34 | +1.49% | 1,623,128 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
CK Life Sciences Intl (Holdings) Inc is an investment holding company principally engaged in the development and sales of healthcare products. The Company operates through two segments. The Health segment is engaged in the development, production, marketing and sales of healthcare and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its pharmaceutical products include cancer-related pharmaceuticals and painkillers, among others. The Agriculture-related Businesses segment is engaged in the operation of vineyards, as well as the development, production, marketing and sales of agriculture and related products. Its agricultural products include fertilizers and crop protection products, among others.
Sector
Food Processing
Calendar
29/07/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -44.35% | 424M | |
| +8.20% | 7.78B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.13% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- 775 Stock
